Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis ; volume:7 ; number:6 ; day:25 ; month:10 ; year:2005 ; pages:1-8 ; date:12.2005
Breast cancer research ; 7, Heft 6 (25.10.2005), 1-8, 12.2005
- Urheber
-
Reis-Filho, Jorge S.
- Beteiligte Personen und Organisationen
-
Milanezi, Fernanda
Carvalho, Silvia
Simpson, Pete T.
Steele, Dawn
Savage, Kay
Lambros, Maryou BK
Pereira, Emilio M.
Nesland, Jahn M.
Lakhani, Sunil R.
Schmitt, Fernando C.
SpringerLink (Online service)
- DOI
-
10.1186/bcr1341
- URN
-
urn:nbn:de:1111-2016032357316
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Reis-Filho, Jorge S.
- Milanezi, Fernanda
- Carvalho, Silvia
- Simpson, Pete T.
- Steele, Dawn
- Savage, Kay
- Lambros, Maryou BK
- Pereira, Emilio M.
- Nesland, Jahn M.
- Lakhani, Sunil R.
- Schmitt, Fernando C.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization
HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 g ene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH)
Neuroendocrine carcinomas of the esophagus: clinicopathological and immunohistochemical features of 43 cases
The clinicopathological and immunohistochemical features of breast carcinomas with signet-ring-cell differentiation
Expression of HNF-1β in cervical carcinomas: an immunohistochemical study of 155 cases
Immunohistochemical expression of HER2 in breast cancer: socioeconomic impact of inaccurate tests
Immunohistochemical analysis of medullary breast carcinoma autoantigens in different histological types of breast carcinomas
HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas
Immunohistochemical validation of COL3A1, GPR158 and PITHD1 as prognostic biomarkers in early-stage ovarian carcinomas
Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization
HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 g ene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH)
Neuroendocrine carcinomas of the esophagus: clinicopathological and immunohistochemical features of 43 cases
The clinicopathological and immunohistochemical features of breast carcinomas with signet-ring-cell differentiation
Expression of HNF-1β in cervical carcinomas: an immunohistochemical study of 155 cases
Immunohistochemical expression of HER2 in breast cancer: socioeconomic impact of inaccurate tests
Immunohistochemical analysis of medullary breast carcinoma autoantigens in different histological types of breast carcinomas
HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas
Immunohistochemical validation of COL3A1, GPR158 and PITHD1 as prognostic biomarkers in early-stage ovarian carcinomas
Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization
HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 g ene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH)
Neuroendocrine carcinomas of the esophagus: clinicopathological and immunohistochemical features of 43 cases
The clinicopathological and immunohistochemical features of breast carcinomas with signet-ring-cell differentiation
Expression of HNF-1β in cervical carcinomas: an immunohistochemical study of 155 cases
Immunohistochemical expression of HER2 in breast cancer: socioeconomic impact of inaccurate tests
Immunohistochemical analysis of medullary breast carcinoma autoantigens in different histological types of breast carcinomas
HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas